恒瑞醫藥(600276.SH):SHR-2173注射液獲得藥物臨牀試驗批准通知書
格隆匯5月14日丨恒瑞醫藥(600276.SH)公佈,子公司廣東恒瑞醫藥有限公司收到國家藥品監督管理局核准簽發關於SHR-2173注射液的《藥物臨牀試驗批准通知書》,將於近期開展臨牀試驗。SHR-2173注射液是公司自主研發的治療用生物製品,能夠通過靶向異常激活的免疫細胞,發揮抗炎和抑制免疫的生物學效應,有望降低自身抗體水平,改善IgA腎病患者的疾病活動狀態,為患者帶來新的治療選擇。目前國內外尚無SHR-2173類似藥物上市或在臨牀研發階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.